PCP
ESPR

Proficio Capital Partners’s Esperion Therapeutics ESPR Stock Holding History

Proficio Capital Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-19
Closed -$1K – 583
2019
Q2 		$1K Sell
19
-72
-79% -$3.38K ﹤0.01% 1719
2019
Q1 		$4K Buy
+91
New +$4.08K ﹤0.01% 1164

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Proficio Capital Partners's ESPR Position: Q3 2019 in Review

Proficio Capital Partners sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 19 shares — an estimated $1K sold.

Proficio Capital Partners first reported a position in ESPR in Q1 2019 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • Proficio Capital Partners reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 19 Esperion Therapeutics shares in Q3 2019, an estimated $1K.
  • Proficio Capital Partners first reported a position in Esperion Therapeutics in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's Esperion Therapeutics position peaked at $4K in Q1 2019.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.